Thu, Feb 26, 2015, 6:04 PM EST - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

Exact Sciences Corporation Message Board

  • cheerleader1002001 cheerleader1002001 Mar 29, 2014 1:37 PM Flag

    EXAS is Now an Acquisition Target

    With FDA approval, EXAS is now an easy acquisition target by a large pharma or medical diagnostics Company that is looking to bolster organic growth. Just look at some of the market-caps out there for big players in the diagnostics business like Roche. Roche alone commands a market-cap of $127 BILLION and can easily use their share price as currency.

    They could make a $4 Billion Dollar offer for EXAS and it wouldn't even move the needle of their capital structure. Anyone recall that legacy blood testing company GenProbe being bought out by Hologic for $3.7 Billion back in April of 2012?

    Does the name Hologic sound familiar???

    It should.
    They bought out the CEO of Exact's previous company "Third Wave".

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Multiply 25 million by $25 for a starting estimate of cost to cover. Quite a risk to sit on.

      • 1 Reply to drc388
      • Cheerleader is right.
        Just take a look at some of the market-caps that the biotech universe trades at.
        Several are well over $100 Billion. Many are $30, $40, $50 Billion.
        Roche is an obvious acquirer.

        If a large company wants to increase their organic growth, acquiring EXAS for a few billion would be like picking up the lunch check for a bunch of Beverly Hill housewives.

    • Right now, what companies do you think would be a good fit for EXAS? What about the major testing outfits like Quest Diagnostics? What would a buyout price look like right now? $18 PPS? Good question.

    • However easy it is to see how the financial side of a buyout might work, it isn't going to happen unless EXAS wants it to. So far the company has gone a long way toward indicating they want to bring their product to market themselves, and they've taken steps to protect themselves from a hostile takeover.

      Since they have other genetic markers for, what are now virtually undetectable digestive system cancers on deck, I think they've got a pretty good idea that they can be a major diagnostics company in their own right. The bids would have to be pretty high to buy all that

      Sentiment: Buy

    • Too much dangerous for short sellers, for little profit they are playing with fire. The day acquisition news comes and EXAS will open at $25 for sure. Down side risk is only $1-2. However, upside risk is more then 4 times from the current price. I read the company profile and noticed 100% FDA approval sometime coming soon.

      Sentiment: Strong Buy

23.36-0.66(-2.75%)Feb 26 4:00 PMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.